A detailed history of Nilsine Partners, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Nilsine Partners, LLC holds 1,182 shares of REGN stock, worth $1.21 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
1,182
Previous 1,159 1.98%
Holding current value
$1.21 Million
Previous $1.02 Billion 11.76%
% of portfolio
0.16%
Previous 0.16%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 22, 2024

BUY
$902.69 - $993.35 $20,761 - $22,847
23 Added 1.98%
1,182 $1.14 Billion
Q4 2023

Jan 24, 2024

SELL
$775.18 - $881.7 $199,996 - $227,478
-258 Reduced 18.21%
1,159 $1.02 Billion
Q3 2023

Nov 01, 2023

BUY
$692.45 - $844.37 $4,154 - $5,066
6 Added 0.43%
1,417 $1.17 Billion
Q2 2023

Jul 21, 2023

BUY
$700.03 - $830.35 $5,600 - $6,642
8 Added 0.57%
1,411 $1.01 Billion
Q1 2023

May 10, 2023

BUY
$680.49 - $826.97 $954,727 - $1.16 Million
1,403 New
1,403 $1.15 Billion

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $110B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Nilsine Partners, LLC Portfolio

Follow Nilsine Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nilsine Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nilsine Partners, LLC with notifications on news.